Uppsala 26th November 2018


Nanexa is awarded a Vinnova grant for the NEX-18 product project

Nanexa has received a grant of 500,000 SEK for the product project NEX-18 * from Sweden’s innovation agency Vinnova through the announcement “Runner up SME Instrument 2018”.

Within the EU’s Horizon 2020 research and innovation program, there is an instrument that supports SMEs, “SME instrument Phase 1”. Funds allocated in this Phase 1 of the call should be used for feasibility study with the aim of moving on to a Phase 2 application where significantly higher amounts can be applied for in grants.

Nanexa qualified for a grant and received a so-called “Seal of Excellence” for its application. However, due to budget restrictions within the Horizon 2020 program, not all eligible companies received funding from the EU. Vinnova has then entered and covered up for the best-ranked Swedish grants that did not receive EU funding, of which Nanexa is one.


The company’s CEO David Westberg comments:

I am very pleased that we have been awarded this grant from Vinnova. Independent administrators from both the EU and Vinnova have evaluated our NEX-18 product project and rated it as excellent, which is obviously a confirmation that we are on the right track.

The grant will be used for a feasibility study prior to the submission of a Phase 2 application to Horizon 2020.


* Improved treatment of two forms of leukemia called MDS and AML (Myelodysplastic Syndrome and Acute Myeloid Leukemia) by reformulating existing drug substance with PharmaShell®.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.